Cue Biopharma Inc. Common Stock (CUE)
Stock · NASDAQ · Health Care
$16.98as of 10/16/2026
Price chart
Active signals
CUE Signal Track Record
How signals performed across all stocks →What CUE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 20 | -4.0% | 35% | September 16, 2026 |
| Volume Spike | 19 | -16.2% | 26% | September 18, 2026 |
| Bollinger Band Breakdown | 18 | +0.5% | 56% | March 30, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -22.0% | 43% | January 14, 2025 |
| Any 20-session window (baseline) | -5.9% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CUE
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead au…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 29
- Website
- www.cuebiopharma.com/
Fundamentals
- 1-day range
- $17.25$18.98
- Market cap
- $113.45M
- P/E (trailing)
- —
- P/E (forward)
- -38.90
- EPS (trailing)
- $-26.99
- Dividend yield
- —
- Beta
- 2.84
- Avg. volume
- 272.1K
How Cue Biopharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 16, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Cue Biopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CUECue Biopharma Inc. Common Stock$16.71▼ 10.50%Market cap $113.45MP/E —$4.97$45.5
- NRXPNRX Pharmaceuticals Inc. Common Stock$2.6▼ 4.06%Market cap $111.95MP/E —$1.62$5.06
- CPIXCumberland Pharmaceuticals Inc. Common Stock$7.18▼ 4.77%Market cap $115.07MP/E —$1.85$9.28
- PLYXPolaryx Therapeutics Inc. Common Stock$1.88▼ 3.59%Market cap $110.66MP/E —$1.85$48.91
- ANIXAnixa Biosciences Inc. Common Stock$2.67▼ 3.96%Market cap $116.70MP/E —$2.32$5.46
- YARWYarrow Bioscience Inc. Common Stock$18.31▼ 8.45%Market cap $116.71MP/E —$18.16$44.28
- BGMBGM Group Ltd. Class A Ordinary Shares$8.65▲ 0.70%Market cap $118.62MP/E —$6.45$303
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CUE Cue Biopharma Inc. Common Stock | $113.45M | — | $16.71 | ▼ 10.50% | $4.97$45.5 |
| NRXP NRX Pharmaceuticals Inc. Common Stock | $111.95M | — | $2.6 | ▼ 4.06% | $1.62$5.06 |
| CPIX Cumberland Pharmaceuticals Inc. Common Stock | $115.07M | — | $7.18 | ▼ 4.77% | $1.85$9.28 |
| PLYX Polaryx Therapeutics Inc. Common Stock | $110.66M | — | $1.88 | ▼ 3.59% | $1.85$48.91 |
| ANIX Anixa Biosciences Inc. Common Stock | $116.70M | — | $2.67 | ▼ 3.96% | $2.32$5.46 |
| YARW Yarrow Bioscience Inc. Common Stock | $116.71M | — | $18.31 | ▼ 8.45% | $18.16$44.28 |
| BGM BGM Group Ltd. Class A Ordinary Shares | $118.62M | — | $8.65 | ▲ 0.70% | $6.45$303 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- These stocks are moving in today's sessionChartMill · 10/9/2026
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · 10/9/2026
- Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU ResponseYahoo · 9/28/2026
- Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?Yahoo · 9/26/2026
- Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria - SlideshowSeekingAlpha · 9/24/2026
- An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slideYahoo · 9/22/2026
- Let's take a look at the stocks that are in motion in today's session.ChartMill · 9/21/2026
- Which stocks are experiencing notable movement on Monday?ChartMill · 9/21/2026
- This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga · 9/18/2026
Insider Activity
Insider Actions →- Meluzio Michael Vincent · August 13, 2026 · Option Exercise13.6K
- Meluzio Michael Vincent · August 13, 2026 · Sale3 @ $31.13
- Meluzio Michael Vincent · August 13, 2026 · Sale4.1K @ $30.35
- Meluzio Michael Vincent · August 13, 2026 · Sale1.5K @ $29.37
- Ray Sumita · August 13, 2026 · Option Exercise18.2K
- Ray Sumita · August 13, 2026 · Sale4 @ $31.13
- Ray Sumita · August 13, 2026 · Sale6.4K @ $30.35
- Ray Sumita · August 13, 2026 · Sale2.4K @ $29.37
- Lin Shao-Lee · August 13, 2026 · Sale10.5K @ $29.48
- Lin Shao-Lee · August 13, 2026 · Sale2.4K @ $28.11
- Lin Shao-Lee · August 13, 2026 · Sale5.4K @ $27.19
- Lin Shao-Lee · August 12, 2026 · Option Exercise109.2K
- Lin Shao-Lee · August 12, 2026 · Sale5.8K @ $27.75
- Lin Shao-Lee · August 12, 2026 · Sale34.2K @ $26.99
- Ahlers James M · July 30, 2026 · Grant51.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 1.7K
- Total value held
- $391
- Institutional holders
- 2
- Unknown1.5K
- Unknown200
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cue Biopharma CUE-221 Meets Phase II Goals for Hives
Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.
Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.